{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:56:11Z","timestamp":1785297371264,"version":"3.55.0"},"reference-count":53,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"DFG German Research Foundation","award":["KR-4371\/1-2"],"award-info":[{"award-number":["KR-4371\/1-2"]}]},{"name":"DFG German Research Foundation","award":["FA-466\/4-2"],"award-info":[{"award-number":["FA-466\/4-2"]}]},{"name":"DFG German Research Foundation","award":["RO-5435\/3-3"],"award-info":[{"award-number":["RO-5435\/3-3"]}]},{"name":"DFG German Research Foundation","award":["314061271- TRR 205"],"award-info":[{"award-number":["314061271- TRR 205"]}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/26345-5"],"award-info":[{"award-number":["2017\/26345-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2016_A96"],"award-info":[{"award-number":["2016_A96"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112969"],"award-info":[{"award-number":["70112969"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent. To date, there is no marker established that predicts treatment response. Mitotane has been shown to inhibit sterol-O-acyl transferase 1 (SOAT1), which leads to endoplasmic reticulum stress and cell death in ACC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate SOAT1 protein expression as a marker of treatment response to mitotane.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>A total of 231 ACC patients treated with single-agent mitotane as adjuvant (n\u2005=\u2005158) or advanced disease therapy (n\u2005=\u200573) from 12 ENSAT centers were included. SOAT1 protein expression was determined by immunohistochemistry on formalin-fixed paraffin-embedded specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Retrospective study at 12 ACC referral centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measure<\/jats:title>\n                    <jats:p>Recurrence-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-one of 135 patients (45%) with adjuvant mitotane treatment had recurrences and 45\/68 patients (66%) with mitotane treatment for advanced disease had progressive disease. After multivariate adjustment for sex, age, hormone secretion, tumor stage, and Ki67 index, RFS (hazard ratio [HR]\u2005=\u20051.07; 95% confidence interval [CI], 0.61-1.85; P\u2005=\u20050.82), and DSS (HR\u2005=\u20051.30; 95% CI, 0.58-2.93; P\u2005=\u20050.53) in adjuvantly treated ACC patients did not differ significantly between tumors with high and low SOAT1 expression. Similarly, in the advanced stage setting, PFS (HR\u2005=\u20051.34; 95% CI, 0.63-2.84; P\u2005=\u20050.45) and DSS (HR\u2005=\u20050.72; 95% CI, 0.31-1.70; P\u2005=\u20050.45) were comparable and response rates not significantly different.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SOAT1 expression was not correlated with clinical endpoints RFS, PFS, and DSS in ACC patients with mitotane monotherapy. Other factors appear to be relevant for mitotane treatment response and ACC patient survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa293","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T04:50:11Z","timestamp":1590382211000},"page":"2642-2653","source":"Crossref","is-referenced-by-count":29,"title":["Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study"],"prefix":"10.1210","volume":"105","author":[{"given":"Isabel","family":"Weigand","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-3249","authenticated-orcid":false,"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-4668","authenticated-orcid":false,"given":"Amanda M F","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Unidade de Suprarrenal, Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM42, Servi\u00e7o de Endocrinologia e Metabologia, Hospital de Cl\u00ednicas; Departamento de Patologia, Faculdade de Medicina da Universidade de S\u00e3o Paulo, Brazil, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Basile","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin at San Luigi Hospital , Orbassano,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kircher","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-4176","authenticated-orcid":false,"given":"Laura-Sophie","family":"Landwehr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schreiner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7408-9816","authenticated-orcid":false,"given":"Maria C N","family":"Zerbini","sequence":"additional","affiliation":[{"name":"Unidade de Suprarrenal, Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM42, Servi\u00e7o de Endocrinologia e Metabologia, Hospital de Cl\u00ednicas; Departamento de Patologia, Faculdade de Medicina da Universidade de S\u00e3o Paulo, Brazil, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5020-2071","authenticated-orcid":false,"given":"Cristina L","family":"Ronchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]},{"name":"Institute of Metabolism and System Research, University of Birmingham , Birmingham,","place":["UK"]},{"name":"Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-1912","authenticated-orcid":false,"given":"Felix","family":"Megerle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3956-0043","authenticated-orcid":false,"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia at ASST Spedali Civili , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4995-8108","authenticated-orcid":false,"given":"Letizia","family":"Canu","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0719-105X","authenticated-orcid":false,"given":"Marco","family":"Volante","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin , Orbassano, Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Paiva","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universit\u00e1rio of Coimbra , Coimbra,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Della Casa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Fondazione Policlinico Gemelli, Catholic University , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6271-5533","authenticated-orcid":false,"given":"Silviu","family":"Sbiera","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":false,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]},{"name":"Comprehensive Cancer Center Mainfranken, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1915","authenticated-orcid":false,"given":"Maria Candida B V","family":"Fragoso","sequence":"additional","affiliation":[{"name":"Unidade de Suprarrenal, Laborat\u00f3rio de Horm\u00f4nios e Gen\u00e9tica Molecular LIM42, Servi\u00e7o de Endocrinologia e Metabologia, Hospital de Cl\u00ednicas; Departamento de Patologia, Faculdade de Medicina da Universidade de S\u00e3o Paulo, Brazil, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-2851","authenticated-orcid":false,"given":"Massimo","family":"Terzolo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin at San Luigi Hospital , Orbassano,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7628-3161","authenticated-orcid":false,"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]},{"name":"Comprehensive Cancer Center Mainfranken, University of W\u00fcrzburg , W\u00fcrzburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"issue":"12","key":"2026041420194663700_CIT0001","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1210\/jc.2013-3020","article-title":"Update in adrenocortical carcinoma","volume":"98","author":"Fassnacht","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2026041420194663700_CIT0002","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2026041420194663700_CIT0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1677\/erc.1.01029","article-title":"Management of patients with adrenal cancer: recommendations of an international consensus conference","volume":"12","author":"Schteingart","year":"2005","journal-title":"Endocr Relat Cancer."},{"issue":"9","key":"2026041420194663700_CIT0004","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","article-title":"Complete responses to mitotane in metastatic adrenocortical carcinoma-a new look at an old drug","volume":"22","author":"Reidy-Lagunes","year":"2017","journal-title":"Oncologist."},{"issue":"4","key":"2026041420194663700_CIT0005","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"23","key":"2026041420194663700_CIT0006","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med."},{"issue":"4","key":"2026041420194663700_CIT0007","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1210\/jc.2016-2894","article-title":"Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma","volume":"102","author":"Berruti","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2026041420194663700_CIT0008","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"Fassnacht","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"2","key":"2026041420194663700_CIT0009","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev."},{"issue":"4","key":"2026041420194663700_CIT0010","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1677\/ERC-08-0103","article-title":"Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly","volume":"15","author":"Daffara","year":"2008","journal-title":"Endocr Relat Cancer."},{"issue":"6","key":"2026041420194663700_CIT0011","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1210\/jc.2010-2676","article-title":"Plasma concentrations of o,p\u2019DDD, o,p\u2019DDA, and o,p\u2019DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study","volume":"96","author":"Hermsen","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2026041420194663700_CIT0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","journal-title":"Eur J Endocrinol."},{"issue":"8","key":"2026041420194663700_CIT0013","doi-asserted-by":"crossref","first-page":"e105855","DOI":"10.1371\/journal.pone.0105855","article-title":"CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma","volume":"9","author":"Ronchi","year":"2014","journal-title":"Plos One."},{"issue":"12","key":"2026041420194663700_CIT0014","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-11-2692","article-title":"Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer","volume":"18","author":"Volante","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2026041420194663700_CIT0015","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1210\/en.2015-1367","article-title":"Mitotane inhibits sterol-o-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells","volume":"156","author":"Sbiera","year":"2015","journal-title":"Endocrinology."},{"issue":"3","key":"2026041420194663700_CIT0016","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0960-894X(98)00011-0","article-title":"Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates","volume":"8","author":"Lee","year":"1998","journal-title":"Bioorg Med Chem Lett."},{"key":"2026041420194663700_CIT0017","article-title":"A phase 1 study of nevanimibe","author":"Smith","year":"2020","journal-title":"Invest New Drugs."},{"issue":"3","key":"2026041420194663700_CIT0018","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-12-0368","article-title":"Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells","volume":"20","author":"Hescot","year":"2013","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2026041420194663700_CIT0019","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1530\/ERC-13-0150","article-title":"Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells","volume":"20","author":"Poli","year":"2013","journal-title":"Endocr Relat Cancer."},{"issue":"66","key":"2026041420194663700_CIT0020","doi-asserted-by":"crossref","first-page":"109924","DOI":"10.18632\/oncotarget.18968","article-title":"Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches","volume":"8","author":"Hescot","year":"2017","journal-title":"Oncotarget."},{"issue":"3","key":"2026041420194663700_CIT0021","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am J Surg Pathol."},{"key":"2026041420194663700_CIT0022","article-title":"Supplementary information","author":"Weigand"},{"issue":"2","key":"2026041420194663700_CIT0023","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer."},{"key":"2026041420194663700_CIT0024","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/clinem\/dgz001","article-title":"The efficacy of mitotane in human primary adrenocortical carcinoma cultures","volume":"105","author":"van Koetsveld","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2026041420194663700_CIT0025","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med."},{"issue":"1","key":"2026041420194663700_CIT0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41598-017-00125-8","article-title":"Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas","volume":"7","author":"Weigand","year":"2017","journal-title":"Sci Rep."},{"issue":"2","key":"2026041420194663700_CIT0027","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/cancers12020359","article-title":"Effects of germline","volume":"12","author":"Altieri","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"12","key":"2026041420194663700_CIT0028","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2217\/pgs.12.116","article-title":"Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study","volume":"13","author":"Zsippai","year":"2012","journal-title":"Pharmacogenomics."},{"issue":"21","key":"2026041420194663700_CIT0029","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1158\/1078-0432.CCR-15-2973","article-title":"Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis","volume":"22","author":"Geng","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2026041420194663700_CIT0030","article-title":"Lipid droplets, potential biomarker and metabolic target in glioblastoma","volume":"3","author":"Geng","year":"2017","journal-title":"Intern Med Rev (Wash D C)."},{"issue":"7747","key":"2026041420194663700_CIT0031","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","article-title":"Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma","volume":"567","author":"Jiang","year":"2019","journal-title":"Nature."},{"issue":"8","key":"2026041420194663700_CIT0032","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/carcin\/bgx058","article-title":"Cholesterol uptake and regulation in high-grade and lethal prostate cancers","volume":"38","author":"Stopsack","year":"2017","journal-title":"Carcinogenesis."},{"issue":"1","key":"2026041420194663700_CIT0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010247","article-title":"Sterol O-acyl transferase 1 as a prognostic marker of adrenocortical carcinoma","volume":"12","author":"Lacombe","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"12","key":"2026041420194663700_CIT0034","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1210\/jc.2013-2281","article-title":"Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma","volume":"98","author":"Kerkhofs","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2026041420194663700_CIT0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1530\/EJE-11-0557","article-title":"High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up","volume":"166","author":"Maucl\u00e8re-Denost","year":"2012","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2026041420194663700_CIT0036","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer."},{"issue":"1","key":"2026041420194663700_CIT0037","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/FTD.0000000000000102","article-title":"Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma","volume":"37","author":"Kerkhofs","year":"2015","journal-title":"Ther Drug Monit."},{"issue":"5","key":"2026041420194663700_CIT0038","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/EJE-18-0342","article-title":"Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients","volume":"179","author":"Arshad","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2026041420194663700_CIT0039","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8111850","article-title":"Mitotane concentrations influence the risk of recurrence in adrenocortical carcinoma patients on adjuvant treatment","volume":"8","author":"Puglisi","year":"2019","journal-title":"J Clin Med."},{"issue":"24","key":"2026041420194663700_CIT0040","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1158\/1078-0432.CCR-09-1587","article-title":"miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer","volume":"15","author":"Soon","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2026041420194663700_CIT0041","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1038\/s41598-017-05777-0","article-title":"Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors","volume":"7","author":"Perge","year":"2017","journal-title":"Sci Rep."},{"issue":"3","key":"2026041420194663700_CIT0042","first-page":"923","article-title":"DNA methylation is an independent prognostic marker of survival in adrenocortical cancer","volume":"102","author":"Jouinot","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2026041420194663700_CIT0043","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jamaoncol.2019.1558","article-title":"Value of molecular classification for prognostic assessment of adrenocortical carcinoma","volume":"5","author":"Assie","year":"2019","journal-title":"JAMA Oncol."},{"issue":"5","key":"2026041420194663700_CIT0044","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1210\/en.2015-2052","article-title":"ATR-101, a selective and potent inhibitor of acyl-CoA acyltransferase 1, induces apoptosis in H295R adrenocortical cells and in the adrenal cortex of dogs","volume":"157","author":"LaPensee","year":"2016","journal-title":"Endocrinology."},{"issue":"4","key":"2026041420194663700_CIT0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-15-0527","article-title":"ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo","volume":"23","author":"Cheng","year":"2016","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"2026041420194663700_CIT0046","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"17","key":"2026041420194663700_CIT0047","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N Engl J Med."},{"issue":"6","key":"2026041420194663700_CIT0048","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician\u2019s update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol."},{"key":"2026041420194663700_CIT0049","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fendo.2016.00099","article-title":"Prognostic factors for adrenocortical carcinoma outcomes","volume":"7","author":"Scollo","year":"2016","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"12","key":"2026041420194663700_CIT0050","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2018-01348","article-title":"Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication","volume":"103","author":"Lippert","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2026041420194663700_CIT0051","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1007\/s12325-019-01050-0","article-title":"Prognostic role of Ki-67 in adrenocortical carcinoma after primary resection: a retrospective mono-institutional study","volume":"36","author":"Zhang","year":"2019","journal-title":"Adv Ther."},{"issue":"1","key":"2026041420194663700_CIT0052","first-page":"58","article-title":"Clinical and molecular prognostic factors in adrenocortical carcinoma","volume":"44","author":"Lib\u00e9","year":"2019","journal-title":"Minerva Endocrinol."},{"issue":"10","key":"2026041420194663700_CIT0053","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa293\/33292887\/dgaa293.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/8\/2642\/33701179\/dgaa293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/8\/2642\/33701179\/dgaa293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:39:06Z","timestamp":1776213546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/8\/2642\/5843694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,5,25]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa293","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,5,25]]}}}